Jane S. Ricciuti, RPh, MS


January 20, 2005

In This Article


The year 2004 ended with the US Food and Drug Administration (FDA) approval of new agents for macular degeneration, overactive bladder, pain management, pediatric leukemia, and mucositis. The approval of these very novel agents fills a void where there is no currently approved therapy or alternatives for some patients and diseases.

This month's column reviews FDA new product approvals and labeling changes for:

Analgesic Agents

  • Prialt (ziconotide) Intrathecal Injection

Antineoplastic Agents

  • Clolar (clofarabine) Injection

Anti-Ulcer Agents and Acid Suppressants

  • Nexium (esomeprazole) Capsules

Chemoprotectant Agents

  • Kepivance (palifermin) Injection

Genitourinary Agents

  • Enablex (darifenacin) Extended-Release Tablets

Ophthalmic Agents

  • Macugen (pegaptinib) Injection

  • Vision Blue (trypan blue) Ophthalmic Solution


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.